@article {Prasad975, author = {Vikas Prasad and Friedemann Zengerling and Jochen P. Steinacker and Christian Bolenz and Meinrad Beer and Thomas Wiegel and Matthias Eiber and Neil Fleshner and Ambros J. Beer}, title = {First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients}, volume = {62}, number = {7}, pages = {975--978}, year = {2021}, doi = {10.2967/jnumed.120.249029}, publisher = {Society of Nuclear Medicine}, abstract = {Synergistic effects of immunotherapy with pembrolizumab or drugs targeting DNA damage, such as olaparib, might be used to overcome the limitations of radioligand therapy (RLT) with 177Lu-prostate-specific membrane antigen (PSMA) in metastasized castration-resistant prostate cancer. Here, we present 2 patients receiving such combination or sequential therapies. Methods: RLT was performed at 6- to 8-wk intervals after the patients either exhausted or were considered unfit for all approved conventional treatments. Patient 1 was on pembrolizumab for his squamous cell carcinoma of the skin, whereas patient 2 received RLT sequentially 4 wk after 3 mo of monotherapy with olaparib. Results: Both patients tolerated RLT without any significant hematotoxicity. Patient 2 showed a radiologic and biochemical response, whereas patient 1 achieved prostate-specific antigen stabilization after 3 therapy cycles. Conclusion: These cases indicate that RLT in combination with pembrolizumab or sequentially after olaparib might be well tolerated in single patients.}, issn = {0161-5505}, URL = {https://jnm.snmjournals.org/content/62/7/975}, eprint = {https://jnm.snmjournals.org/content/62/7/975.full.pdf}, journal = {Journal of Nuclear Medicine} }